List of Excipients in Branded Drug BACITRACIN

« Back to Dashboard

Generic Drugs Containing BACITRACIN

Company	Ingredient	NDC	Excipient
Padagis US LLC	bacitracin	0574-4022	MINERAL OIL
Padagis US LLC	bacitracin	0574-4022	PETROLATUM
Rebel Distributors Corp	bacitracin	42254-003	MINERAL OIL

What are the Most Frequently-Used Excipients in BACITRACIN?

# Of NDCs	Excipient
3	MINERAL OIL
3	PETROLATUM

Bacitracin Excipient Strategy and Commercial Opportunities

Last updated: September 28, 2026

Bacitracin is a mature polypeptide antibiotic with limited composition-of-matter patent protection and substantial commercial dependence on formulation execution. The strongest opportunities are in topical semisolids, ophthalmic ointments, preservative-free packaging, veterinary products, and differentiated wound-care combinations. Excipient selection must address bacitracin’s peptide instability, water sensitivity, zinc-complex behavior, antimicrobial compatibility, and patient tolerability.

What pharmaceutical products contain bacitracin?

Bacitracin is marketed primarily as bacitracin zinc for topical use. It appears in single-ingredient and combination products with neomycin, polymyxin B, corticosteroids, anesthetics, moisturizers, and wound-care excipients.

Product category	Typical active form	Common dosage form	Principal commercial use
OTC topical antibiotic	Bacitracin zinc	Ointment, cream, gel	Minor cuts, scrapes, and burns
Prescription ophthalmic	Bacitracin or bacitracin zinc	Sterile ophthalmic ointment	Bacterial eye infections and periocular use
Combination topical	Bacitracin zinc with polymyxin B, neomycin, or other actives	Ointment or cream	Broad-spectrum topical infection control
Veterinary	Bacitracin zinc or related bacitracin preparations	Premix, soluble powder, ointment	Livestock, poultry, companion-animal products
Research and industrial	Bacitracin	Powder or solution	Cell-culture selection, biochemical applications

Bacitracin is a cyclic polypeptide complex produced by Bacillus species. Bacitracin A is generally treated as the principal active component, while commercial bacitracin zinc contains a mixture of related bacitracins complexed with zinc.

In the United States, topical bacitracin products fall largely within the FDA’s OTC topical antimicrobial framework under 21 C.F.R. Part 333. The product category is regulated primarily through monograph requirements, manufacturing controls, labeling, and product-specific FDA review where applicable.

What excipients are used in bacitracin formulations?

The most established excipient platform is an anhydrous or low-water petrolatum-based ointment. Typical excipients include white petrolatum, mineral oil, paraffin, lanolin derivatives, polyethylene, waxes, glycols, emulsifiers, and viscosity modifiers.

Excipient class	Examples	Function in bacitracin products	Key risks
Hydrocarbon bases	White petrolatum, mineral oil, paraffin	Occlusion, skin coverage, moisture retention	Greasiness, poor washability
Waxes and stiffeners	Microcrystalline wax, paraffin wax, polyethylene	Structure, thermal stability, spread control	Drag during application
Emollients	Lanolin, hydrogenated oils, fatty esters	Skin feel and barrier support	Sensitization and oxidation
Polyols	Propylene glycol, polyethylene glycol, glycerol	Solubilization, humectancy, texture	Irritation, water activity changes
Emulsifiers	Sorbitan esters, polysorbates, glyceryl esters	Oil-water compatibility	Peroxide formation, preservative interaction
Gelling agents	Carbomers, cellulose derivatives, poloxamers	Gel structure and suspension	Ionic incompatibility and viscosity drift
Antioxidants	Tocopherol, butylated hydroxytoluene, sulfites	Protection of oxidizable excipients	Sensitivity and regulatory limits
Chelators	Edetate salts	Metal-ion control	Potential interaction with zinc
Preservatives	Phenoxyethanol, parabens, benzalkonium chloride	Microbial control in aqueous systems	Ocular irritation and adsorption
Buffers	Phosphate, citrate, borate systems	pH control	Zinc precipitation or peptide degradation

Hydrocarbon ointments are commercially attractive because they limit water-driven degradation and do not require a conventional preservative in a properly controlled, single-use or multi-use package. Their disadvantages are poor cosmetic acceptability, difficult removal, and limited suitability for large-area or hairy-skin application.

How should excipients be selected for bacitracin stability?

Excipient strategy should begin with moisture control, metal-ion control, pH control, and microbial-risk assessment.

Bacitracin is a peptide with functional groups that can interact with metals, surfactants, buffers, and preservatives. The zinc complex may improve handling and active recovery, but formulation changes can alter the balance between free bacitracin, zinc-associated species, and related components.

Water activity and hydrolysis

Anhydrous ointments generally provide the lowest formulation risk. Creams, gels, lotions, and aqueous solutions require a defined stability program covering:

• Bacitracin potency and related substances
• Water activity
• pH drift
• Zinc content and extractable zinc
• Phase separation
• Microbial limits
• Preservative effectiveness
• Container interaction

Water-containing systems should use validated preservative systems and packaging that limits repeated microbial ingress. A low-water emulsion can offer improved patient acceptability while reducing degradation relative to a conventional aqueous cream.

Zinc compatibility

Bacitracin zinc creates a particular excipient constraint. Strong chelators, phosphate-rich buffers, and certain anionic polymers can alter zinc availability or produce precipitation. Edetate salts may improve microbial control or reduce trace-metal catalysis, but they can also interact with zinc and must be evaluated against assay, dissolution, and impurity data.

Formulators should avoid relying on nominal pH alone. The relevant variables include ionic strength, counterions, zinc concentration, polymer charge, and the ratio of water to oil phase.

Surfactants and preservatives

Nonionic surfactants are usually easier to manage than strongly ionic surfactants, but they can still affect peptide conformation, partitioning, and container adsorption. Cationic preservatives such as benzalkonium chloride are established in ophthalmic products but can cause ocular irritation and may be unsuitable for chronic or large-area topical use.

Preservative-free packaging is a commercial option for ophthalmic and sensitive-skin products. Unit-dose tubes, blow-fill-seal containers, and airless pumps can reduce preservative exposure, although extractables, oxygen transmission, dose uniformity, and device approval requirements become more important.

What formulations are protected by bacitracin patents?

Bacitracin’s core antibiotic chemistry is longstanding and does not provide a meaningful modern composition-of-matter exclusivity position. Commercial differentiation depends more heavily on formulation, delivery system, manufacturing process, packaging, brand, and regulatory status.

Potentially protectable subject matter includes:

• Low-water topical ointments with defined bacitracin recovery
• Non-greasy emulsions or hydrogels
• Preservative-free ophthalmic delivery systems
• Sustained-release wound dressings
• Bacitracin combinations with barrier-repair agents
• Nanostructured or polymeric delivery systems
• Stabilized veterinary feed or drinking-water formulations
• Manufacturing processes that improve potency or impurity control
• Packaging systems that reduce oxidation, moisture ingress, or dose variability

These claims face substantial validity and enforceability challenges because bacitracin formulations have been used for decades. A defensible patent position would require a specific technical effect, such as improved stability, reduced irritation, enhanced tissue retention, or demonstrated manufacturing performance.

How strong is the bacitracin patent estate?

The overall estate is weak for the active ingredient and stronger only in narrow, product-specific areas.

Estate component	Commercial strength	Reason
Bacitracin composition patents	Very low	Historic active ingredient
Bacitracin zinc complexes	Low	Longstanding pharmaceutical use
Basic petrolatum ointments	Very low	Extensive prior art
Ophthalmic ointment vehicles	Low to moderate	Claim scope depends on formulation details
Preservative-free packaging	Moderate	Device and container claims may remain relevant
Advanced wound dressings	Moderate	Performance-based claims may create differentiation
Manufacturing and impurity control	Moderate	Process know-how may be difficult to design around
Combination products	Low to moderate	Depends on combination, indication, and clinical evidence

No broad patent barrier should be assumed for a conventional bacitracin ointment. Freedom-to-operate analysis should focus on current formulation, packaging, device, combination, and manufacturing patents rather than historic bacitracin patents.

When does bacitracin lose exclusivity?

Bacitracin has already lost basic market exclusivity. The relevant commercial question is not the expiration of a single patent but whether a product is sold under an OTC monograph, an approved prescription application, or a regulated veterinary pathway.

Regulatory pathway	Exclusivity position	Entry implication
OTC topical monograph	No conventional branded patent monopoly	Multiple manufacturers can compete if requirements are met
Prescription ophthalmic product	Application-specific patents and regulatory exclusivities may apply	Entry depends on approved product status and listed protections
Combination topical product	Depends on active ingredients and regulatory pathway	Labeling and formulation similarity are critical
Veterinary product	Product-specific approval or monograph status	Manufacturing, residue, and species claims affect entry
Compounded preparation	Not a substitute for commercial approval	Quality, sterility, and distribution restrictions apply

Bacitracin is not a biologic, so biosimilar competition is not applicable. The relevant competitors are generic, OTC, private-label, contract-manufactured, and veterinary products.

What is the Orange Book status of bacitracin?

The Orange Book is relevant to approved prescription drug applications, not to the broad OTC monograph market. Conventional OTC bacitracin ointments do not obtain market protection through Orange Book listings in the same manner as new prescription drugs.

For prescription ophthalmic products, Orange Book status depends on the specific approved application and product sponsor. A complete commercial assessment must distinguish:

1. Products marketed under an approved NDA.
2. Products relying on an ANDA.
3. OTC monograph products.
4. Unapproved or legacy products sold through nonstandard channels.
5. Veterinary products, which are outside the human Orange Book system.

The presence of an Orange Book listing would not by itself establish a meaningful market barrier. The commercial value depends on active patents, listed claims, application status, regulatory exclusivity, and whether a generic applicant can certify against listed patents.

Which companies are challenging bacitracin products?

The market is characterized by distributed generic and private-label competition rather than a single high-profile patent challenge. Major branded and generic consumer-health companies have historically marketed bacitracin-containing products, including products sold under retailer brands and combination antibiotic brands.

Competition typically occurs through:

• OTC private-label ointments
• Generic prescription ophthalmic ointments
• Combination antibiotic products
• Veterinary manufacturers
• Contract development and manufacturing organizations
• Wound-care companies using bacitracin in dressings or kits

Paragraph IV litigation is not the central competitive mechanism for ordinary OTC bacitracin ointments. Where a prescription product has listed patents, an ANDA applicant could use a Paragraph IV certification, but the likelihood of commercially material litigation depends on the specific application and patent listings.

What patent litigation affects bacitracin?

Bacitracin is not associated with a current, widely recognized patent litigation campaign comparable to newer branded antibiotics, biologics, or specialty drugs. Litigation risk is more likely to arise from:

• Combination-product patents
• Ophthalmic delivery systems
• Wound-dressing technologies
• Packaging and dispensing systems
• Manufacturing processes
• Trademark and trade-dress disputes
• Product liability and labeling claims

The absence of a broad patent campaign does not eliminate product risk. Topical antibiotics face regulatory scrutiny related to allergic reactions, antimicrobial resistance, inappropriate use, and consumer labeling.

What excipient-led commercial opportunities exist for bacitracin?

1. Low-grease topical ointments

A petrolatum-dominant base is effective but cosmetically weak. A low-grease formulation using a structured emulsion, volatile emollient, or polymer-supported hydrogel could target consumers who reject conventional antibiotic ointments.

The product would need to preserve bacitracin potency while demonstrating acceptable microbial control, skin tolerability, and packaging compatibility.

2. Preservative-free ophthalmic products

Preservative-free single-dose packaging can target patients with ocular sensitivity or repeated dosing needs. The opportunity depends on sterile manufacturing economics, container performance, and a clinically acceptable delivery volume.

Key development risks include adsorption to polymeric containers, extractables, particulate control, and unit-dose waste.

3. Wound-care combinations

Bacitracin can be combined with non-antibiotic barrier ingredients such as petrolatum, dimethicone, zinc oxide, panthenol, or selected skin-conditioning agents. These products may command higher prices than plain bacitracin, although combination claims must remain consistent with the regulatory pathway.

A commercial strategy should avoid unnecessary antibiotic combinations where the consumer benefit is not clear. Antimicrobial stewardship concerns can limit broad-use positioning.

4. Advanced dressings

Bacitracin-loaded films, hydrogels, foams, and nonwoven dressings could create differentiated delivery and reduce repeated application. The regulatory classification may become more complex if the dressing makes drug-delivery or infection-treatment claims.

Potential advantages include controlled local exposure, reduced mess, improved adherence, and integration into first-aid kits.

5. Veterinary formulations

Veterinary products remain a distinct opportunity because species, route, dosing, feed compatibility, and residue requirements create barriers that are not present in ordinary OTC topical products. Water-soluble or feed-compatible systems can be commercially useful, but the regulatory burden is product-specific.

6. Contract manufacturing and private label

The mature active ingredient and standardized ointment technology support private-label production. Competitive advantage is more likely to come from:

• Reliable bacitracin zinc supply
• Low impurity and bioburden profiles
• Flexible tube and pump filling
• Short development cycles
• Stable emulsions and gels
• Retailer-specific packaging
• Small-batch clinical or professional products

How does bacitracin compare with competing topical antibiotics?

Attribute	Bacitracin	Mupirocin	Neomycin	Polymyxin B
Main market	OTC topical and combination products	Prescription topical	OTC combination products	OTC and prescription combinations
Formulation platform	Ointments, creams, ophthalmic products	Ointment and cream	Ointment combinations	Ointment and ophthalmic combinations
Patent maturity	Very mature	More product-specific protection historically	Mature	Mature
Allergy concern	Present	Present but generally product-specific	Notable contact sensitization concern	Lower systemic use but local reactions possible
Differentiation opportunity	Delivery, packaging, wound care	Clinical positioning and formulation	Combination and labeling	Combination and ophthalmic delivery
Generic pressure	High	High but prescription-channel dependent	High	High

Bacitracin is commercially attractive where the product can improve usability or fit a defined wound-care niche. It is less attractive as an undifferentiated commodity ointment.

What are the FDA regulatory risks for bacitracin products?

FDA-related risks include failure to meet OTC monograph conditions, inaccurate active-ingredient labeling, inadequate stability data, preservative failure, microbial contamination, and unsupported combination claims.

Topical products must also address contact dermatitis and consumer misuse. Ophthalmic products face higher requirements for sterility, particulate control, container closure integrity, and ocular tolerability.

A reformulated product may require more than an excipient change if the delivery system alters drug release, local exposure, route of administration, or product classification. The sponsor should treat any change from an anhydrous ointment to an aqueous gel, emulsion, dressing, or device-assisted system as a potential regulatory requalification event.

What generic launch scenarios exist for bacitracin?

The most likely launch scenarios are:

1. Private-label OTC ointment using a conventional petrolatum base.
2. Generic ophthalmic ointment where an approved reference product and pathway are available.
3. Combination antibiotic ointment with retailer or pharmacy distribution.
4. Premium preservative-free product in single-dose packaging.
5. Bacitracin-containing wound dressing with differentiated delivery.
6. Veterinary product targeting a defined species or application.

The lowest-risk launch is a conventional topical ointment. The highest commercial upside is in ophthalmic packaging, advanced wound care, and products that solve cosmetic or adherence problems.

Key Takeaways

• Bacitracin’s active-ingredient patent position is mature and commercially weak.
• Conventional petrolatum ointments remain the lowest-risk formulation platform.
• The main technical constraints are peptide stability, zinc compatibility, moisture control, preservative performance, and sterility.
• OTC monograph competition is more important than Orange Book exclusivity for ordinary topical products.
• Biosimilar risk does not apply because bacitracin is a small-molecule-derived peptide antibiotic, not a biologic.
• The strongest formulation opportunities are preservative-free ophthalmic products, low-grease topical systems, advanced wound dressings, and veterinary formulations.
• Patent value is most likely to arise from delivery systems, packaging, manufacturing controls, and demonstrable formulation performance.
• Commercial success depends more on product usability, retail positioning, regulatory execution, and manufacturing reliability than on historic bacitracin patents.

FAQs

Is bacitracin zinc more stable than bacitracin in topical formulations?

Bacitracin zinc is widely used because the zinc-associated form is practical for pharmaceutical manufacture and topical delivery. Stability depends on the complete formulation, including water activity, pH, excipients, packaging, and impurity profile.

Can bacitracin be formulated in a hydrogel?

Yes. Hydrogels are technically feasible, but they require control of water-driven degradation, preservative effectiveness, zinc-polymer interactions, viscosity, and drug distribution. A hydrogel may improve spreadability while increasing formulation and regulatory complexity.

Are bacitracin products suitable for preservative-free packaging?

Yes. Preservative-free bacitracin products are most commercially plausible in unit-dose ophthalmic containers or packaging systems that minimize repeated microbial ingress. The product still requires sterility and container-closure validation.

Does bacitracin have biosimilar competition?

No. Bacitracin is not regulated as a biologic reference product for biosimilar purposes. Competition comes from generic, OTC, private-label, and veterinary products.

What is the best excipient platform for a low-cost bacitracin product?

An anhydrous white-petrolatum-based ointment is generally the most economical platform. It minimizes water-related stability risk, uses familiar manufacturing equipment, and supports broad topical positioning.

References

1. Code of Federal Regulations. (2024). 21 C.F.R. Part 333, subpart B: Topical antimicrobial drug products for over-the-counter human use. U.S. Government Publishing Office.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2020). Bacitracin for injection: Drug safety communication and market withdrawal information. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2016). Nonprescription topical antimicrobial drug products: Regulatory information and labeling requirements. Center for Drug Evaluation and Research.

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Bacitracin and bacitracin zinc monographs. Rockville, MD: U.S. Pharmacopeial Convention.

6. World Health Organization. (2023). WHO guidelines on quality assurance of pharmaceutical products. Geneva, Switzerland: World Health Organization.